+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A serum exosomal microRNA panel as a potential biomarker test for gastric cancer

A serum exosomal microRNA panel as a potential biomarker test for gastric cancer

Biochemical and Biophysical Research Communications 493(3): 1322-1328

The findings from several studies have suggested that circulating miRNAs are imbalanced with the genesis of gastric cancer (GC). Both normal and cancer cells can generate and secrete exosomes, which are nanosized membrane vesicles that can transport microRNAs and proteins. Emerging evidence indicates that the exosomes secreted by cancer cells can be released into the circulatory system. In this study, we investigated whether circulating exosomal miRNAs can be used to discriminate individuals with GC from healthy controls (NCs). Based on the quantitative reverse transcription polymerase chain reaction (qRT-PCR), four miRNAs (miR-19b-3p, miR-17-5p, miR-30a-5p, and miR-106a-5p) related to GC pathogenesis were identified in serum-circulating exosomes from a cohort of 20 healthy controls and 20 individuals with GC in the initial screening phase. The distinguished miRNAs were further validated in the training (90 GC vs. 90 NCs) and blinded phases 20 GC vs. 20 NCs), and the area under receiver operating characteristic (ROC) curves of these miRNAs were analyzed. We found that miR-19b and miR-106a were markedly overexpressed in individuals with GC compared to NCs (P < 0.0001). Besides, the ROC analyses yielded the AUC values of 0.786 for miR-106a-5p, 0.769 for miR-19b-3p and combined ROC analysis revealed the highest AUC value of 0.814 in discriminating GC patients from NCs. Furthermore, based on the model developed from the data, a signature composed of the 2 miRNAs (miR-19b-3p and miR-106a-5p) correctly discriminated 19 out of 20 GC serum samples (95% sensitivity) and 18 out of 20 normal samples (90% specificity) in the blinded phase. Moreover, the validated miRNAs were related to GC lymphatic metastasis (P < 0.01) and expressed at higher levels in stages III and IV compared to I and II stages (P < 0.05). These results suggest that serum exosomal miR-19b-3p and miR-106a-5p are novel potential biomarkers for detecting GC.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 059403876

Download citation: RISBibTeXText

PMID: 28986250

Related references

Serum microRNA panel excavated by machine learning as a potential biomarker for the detection of gastric cancer. Oncology Reports 39(3): 1338-1346, 2018

Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Molecular Cancer 17(1): 68, 2018

Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. Journal of Cellular and Molecular Medicine 23(2): 1396-1405, 2019

Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer. Journal of Cancer 9(15): 2659-2665, 2018

Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma. Journal of Pediatric Surgery 52(4): 618-624, 2017

Exosomal MicroRNA in Peripheral Serum as a Noninvasive Diagnostic Biomarker for Glioblastoma. Neurosurgery 85(2): E176-E177, 2019

Exosomal microRNA: a novel biomarker for breast cancer. Biomarkers in Medicine 12(2): 177-188, 2018

Circulating microRNA-133, microRNA-17 and microRNA-25 in serum and its potential diagnostic value in gastric cancer. Journal of Cellular Biochemistry 120(8): 12376-12381, 2019

Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Diabetic Nephropathy in Rats. Plos one 11(4): E0154055, 2016

MicroRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Research 78(7): 1833-1844, 2018

Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer. Oncology 92(6): 360-370, 2017

Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer. Disease Markers 2015: 435656, 2015

A two-microRNA signature as a potential biomarker for early gastric cancer. Oncology Letters 7(3): 679-684, 2014

Serum microRNA expression profile as a diagnostic panel for gastric cancer. Japanese Journal of Clinical Oncology 46(9): 811-818, 2016

Serum exosomal microRNA let-7i-3p as candidate diagnostic biomarker for Kawasaki disease patients with coronary artery aneurysm. Iubmb Life 71(7): 891-900, 2019